News: Brokerage

Industry City grows biotech footprint with over 61,000 s/f of new and expanded leases

Brooklyn, NY Industry City, the 35-acre, six million s/f mixed-use campus in Sunset Park, signed 61,510 s/f of new and expanded leases. 

Biotechnology company Cresilon has signed a 55,000 s/f, 10-year expansion lease for its U.S. headquarters and lab space, more than doubling its footprint from 27,000 s/f. 

Therapeutic discovery company Rumi Scientific has signed a five-year, 6,510 s/f lease at Building 4 for its research and development lab.

Senior vice president of leasing for Industry City, Jeff Fein, represented the landlord in the Cresilon deal; CBRE vice president Josh Pernice represented Cresilon. Fein and Nick Shears, vice president of leasing for Industry City, represented the landlord in the Rumi Scientific deal.

Cresilon, Inc. is a Brooklyn-based, privately-held medical device company focused on hemostatic technologies that improve wound care and advance the standard of medical treatments. Founded by Joe Landolina from his New York University dorm room, Cresilon developed a plant-based gel that stops life-threatening bleeding in seconds. Alongside co-founder and fellow NYU alum Isaac Miller, Landolina has helped scale Cresilon into a leading biomedical company, attracting over $100 million in funding.

Rumi Scientific is a biotechnology company pioneering new approaches to therapeutic discovery for neurological and kidney diseases. Using its proprietary human tissue modeling platform, Rumi accelerates the identification and development of novel drug candidates to treat a wide range of disorders.

Industry City has seen a notable uptick in biotech leasing, driven by growing demand for flexible lab infrastructure and the campus’s strategic positioning – offering companies a rare mix of connectivity, purpose-built space that unlocks operational efficiencies, and a dynamic campus culture that supports both innovation and talent retention.

“Cresilon’s expansion at Industry City is especially rewarding because it reflects a years-long partnership supporting their growth and ensuring they have the right space to scale,” said Fein. “With Rumi Scientific joining the campus, we’re excited to build a similar partnership and further grow an ecosystem where biotech innovators thrive alongside like-minded peers in a supportive, future-focused environment.”

Cresilon’s expanded space will allow the company to considerably increase its manufacturing capacity and continue to drive advancements in revolutionary medical technologies with facilities for research, development and manufacturing. Rumi Scientific will relocate from its current lab space at the New York Blood Center to an office and lab facility in Building 4. The companies join a growing list of biotech companies at Industry City, including Phoenix Nest and AOM Fusion.

“Industry City’s partnership over the past decade has played a critical role in Cresilon’s growth, from inventing new lifesaving products in our original lab space to receiving FDA approval during our time on campus, and we’re excited to deepen our roots with an expanded presence,” said Landolina. “The vibrant campus life, with its energy, amenities, and sense of connection, has created an environment our employees are energized by – which has been instrumental in our company reaching our next phase of growth.”

“Rumi looks forward to bringing its headquarters to Industry City, which shares the spirit of collaboration and community that our company is founded on,” said Ignacio Muñoz-Sanjuán, CEO at Rumi Scientific “With the support of a vibrant, innovation-driven campus, we’re well-positioned to accelerate our efforts to find treatments for some of the most challenging neurological diseases.”

READ ON THE GO
DIGITAL EDITIONS
Subscribe
Columns and Thought Leadership
The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

There was a time when an offering memorandum (OM) was pretty bare bones, some photos, a few bullet points on income, and a rent roll thrown in at the back. That used to get the job done. Not anymore. In 2025, buyers are sharper, faster, and more selective. They’re looking
The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

July 1, 2025 is the deadline for US banks to begin to adopt Basel III banking standards and July 14, 2025 is the deadline for U.S. banks to adopt ISO 20022 messaging standards. Both will have a significant effect on the banking and commercial real estate (CRE) finance sectors.
Tri-state capital  migrates nationally amid  regulation pressure - by Reese Weaver

Tri-state capital migrates nationally amid regulation pressure - by Reese Weaver

New York tri-state multifamily investors are increasingly reallocating capital to less-regulated markets across the U.S. as rent control and legislative risk erode returns at home. With over 60% of New York City’s rental housing stock classified as rent-stabilized, the traditional value-add model — buying under-performing buildings,

A fresh start - by Shallini Mehra and Amit Doshi

A fresh start - by Shallini Mehra and Amit Doshi

For the past several years, the New York City multifamily housing market has been defined by disruption. The combined impact of the HSTPA rent laws and a sharply higher interest rate environment has fundamentally reduced